NEW_CURA-LEAF_1170x120_OCT

RxCrossroads

McKesson buys RxCrossroads

SAN FRANCISCO — McKesson Corp. has agreed to buy RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health. The deal, expected to close early next year, is valued at $735 million, or about $635 million net of the present value of incremental cash tax benefits. It will be funded by

McKesson to buy RxCrossroads from CVS for $735 million

McKesson to buy RxCrossroads from CVS for $735 million

SAN FRANCISCO — McKesson Corp. announced late Monday that it had signed a definitive agreement to purchase RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health. The transaction is valued at $735 million, or approximately $635 million net of the present value ofincremental cash tax benefits, and will be funded by